Academic Licensing Exclusive worldwide license from NYU to develop and commercialize GL-12 creates a clear path for co-development and collaboration with pharma/biotech partners seeking cardiovascular innovations, offering access to NYU IP and the potential to expand the program through further partnerships.

Pulmonary Biologics XTMAB-16 anti-TNFα monoclonal antibody is in mid-stage clinical development for pulmonary sarcoidosis, with an exclusive North America licensing deal with Meitheal. This opens doors for regional development and commercialization partnerships, contract manufacturing, and supply agreements for a high-priority biologic asset.

Funding Momentum Recent growth equity funding and a new corporate headquarters signal strong financing and scalability readiness, enabling late-stage development and broader outreach to potential licensing, co-development, and commercialization partners.

Global Reach Based in Chicago with a compact, agile team and active global collaborations, Xentria can act as a regional hub for North American operations while pursuing international partnerships, offering flexible engagement models for pharma partners.

Patient Centric Focus Xentria’s emphasis on patient engagement, diversity, and sustainability provides a differentiator for partners prioritizing patient-centric trial design and outcomes, enabling collaborative opportunities around patient recruitment, engagement programs, and sustainable development practices.